Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 52Triple Negative Breast Neoplasms 10Lung Neoplasms 6Stomach Neoplasms 5Sarcoma 3Neoplasm Metastasis 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Breast Cancer 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1nazartinib 1canakinumab 1alectinib 1Tinzaparin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × Injections × Breast × Clear all
NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Cancer Hospital

Phase 1/2 Not yet recruiting
96 enrolled
BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡